LAI aripiprazole: An optimal treatment option for schizophrenia
11 Apr 2019
Schizophrenia is a highly debilitating mental condition, affecting more than 21 million people globally. It is characterized by delusions, hallucinations, and other symptoms which impair social and occupational functions.1 Schizophrenia imposes substantial health, social and economic burden. In Malaysia,the total costs of schizophrenia were estimated at USD100 million in 2013; of which 72% was attributed to indirect cost or productivity loss, followed by direct medical cost (26%).2 The enormous economic burden of schizophrenia is suggestive of an inadequate provision of healthcare services to these patients. Alarmingly, treatment nonadherence is associated with substantial direct medical costs that extend beyond the cost of rehospitalization to other outpatient services and medication costs,3,4 highlighting the need to improve treatment adherence to antipsychotic medication.
Related MIMS Drugs